# DESCRIPTION

## BACKGROUND

- describe intestinal barrier function
- discuss importance of intestinal barrier
- mention loss of intestinal barrier function
- introduce relationship between intestinal barrier and diseases

## SUMMARY

- introduce S3QELs
- describe S3QELs' effect on intestinal permeability
- mention feeding S3QELs to Drosophila and mice
- describe results of S3QELs on intestinal permeability
- introduce embodiments of methods for treating intestinal permeability
- describe embodiment 1: method for treating intestinal permeability
- describe embodiment 2: method with agent that partially suppresses superoxide generation
- describe embodiment 3: method with S3QEL
- describe embodiment 4: method with sulfanyloxoquinazoline structural group S3QEL
- describe embodiment 5: method with specific S3QELs
- describe embodiment 6: method with pyrazolopyrimidine structural group S3QEL
- describe embodiment 7: method with specific S3QELs
- describe embodiment 8: method with specific S3QELs
- describe embodiment 9: method with specific S3QELs
- describe embodiment 10: method with specific S3QELs
- describe embodiment 11: method with specific S3QELs
- describe embodiment 12: method with specific S3QELs
- describe embodiment 13: method with specific S3QELs
- describe embodiment 14: method with specific S3QELs
- describe embodiment 15: method with specific S3QELs
- describe embodiment 16: method with specific S3QELs
- describe embodiment 17: method with specific S3QELs
- describe embodiment 18: method with specific S3QELs
- describe embodiment 19: method with specific S3QELs
- describe embodiment 20: method with specific S3QELs
- describe embodiment 21: method with specific S3QELs
- describe embodiment 22: method with specific S3QELs
- describe embodiment 23: method with delivery vehicle
- describe embodiment 24: method with lipid or liposome formulation

## Definitions

- define mammal
- define subject
- define effective amount
- define therapeutically effective amount
- define prophylactically effective amount
- define treatment
- define mitigating
- define intestinal barrier
- define intestinal permeability

## DETAILED DESCRIPTION

- demonstrate S3QELs protect against intestinal permeability and apoptotic cell number
- describe results of feeding S3QELs to mammals on a high-fat diet
- summarize observations on superoxide production from complex III in enterocytes
- introduce method for treatment or prophylaxis of age-related and/or pathology-associated increase in intestinal barrier permeability
- describe embodiments of methods for treatment or prophylaxis of diet-induced intestinal permeability
- describe embodiments of methods for treatment or prophylaxis of age-related increases in intestinal permeability
- describe embodiments of methods for treatment or prophylaxis of pathology-associated increase in intestinal barrier permeability
- summarize therapeutic treatment that ameliorates one or more symptoms of a pathology associated with intestinal permeability

### Celiac Disease and Ulcerative Colitis (UC)

- describe intestinal barrier dysfunction in celiac disease and ulcerative colitis
- summarize observations on increased intestinal permeability in celiac disease
- describe consequences of impaired epithelial barrier in celiac disease
- describe alterations in epithelial tight junctions in inflammatory bowel disease
- summarize observations on prion protein dislocation in IBD
- describe increased incidence of apoptotic events in IBD
- describe role of proinflammatory cytokines in IBD
- summarize etiology of IBD
- describe insufficient mucosal response to bacterial stimuli in IBD
- describe intestinal barrier dysfunction in irritable bowel syndrome
- summarize observations on increased intestinal permeability in IBS
- describe structural changes in epithelial cells in IBS

### Parkinson's Disease and Alzheimer's Disease.

- describe brain-gut axis interactions in Parkinson's disease
- summarize observations on gut dysbiosis and increased intestinal permeability in PD
- describe role of innate immune system in PD
- describe adaptive immune system disturbance in PD
- summarize observations on gut microbiota changes in neurodegenerative diseases
- describe role of lipopolysaccharide in AD pathology
- summarize observations on microbiome-derived LPS in AD brains

### Active Agents.

- introduce method involving administration of S3QELs
- describe role of site IIIQo electron leak in ROS-mediated signaling and pathologies
- summarize high-throughput chemical screening to identify S3QELs
- describe illustrative S3QELs
- summarize availability of S3QELs from commercial suppliers
- describe screening protocols to identify S3QELs
- summarize desirable properties of S3QELs

### Permeability Assays

- introduce permeability assays
- describe administration of non-digestible markers
- explain principle of non-digestible markers
- list types of non-digestible markers
- describe use of fluorescent-labeled dextrans
- detail protocol for FITC-dextran administration
- explain measurement of serum FITC-dextran concentration
- introduce non-metabolizable oligosaccharides
- describe lactulose-mannitol test
- explain advantages of lactulose-mannitol test
- introduce triple sugar test
- describe multi sugar test
- list diseases with increased permeability for saccharides
- introduce PEGs as permeability markers
- describe advantages of PEGs
- introduce fecal albumin as permeability marker
- explain principle of fecal albumin measurement
- describe albumin properties
- explain measurement of albumin in fecal samples
- introduce intestinal biomarkers
- describe zonulin as biomarker
- explain role of zonulin in intestinal permeability
- introduce calprotectin as biomarker
- explain role of calprotectin in intestinal inflammation
- introduce Alpha-1-Antitrypsin (A1AT) as biomarker
- explain role of A1AT in intestinal permeability
- introduce lipopolysaccharide (LPS) as biomarker
- explain role of LPS in endotoxemia
- introduce circulating Endotoxin Core Antibodies (EndoCAb)
- explain role of EndoCAb in intestinal barrier damage
- introduce plasma D-lactate level as biomarker
- explain role of plasma D-lactate level in intestinal permeability

### Pharmaceutical Formulations.

- administer S3QELs as pharmaceutical formulation
- describe salt forms of S3QELs
- prepare salts using standard procedures
- define pharmaceutically acceptable salt
- list suitable anionic salt forms
- list suitable cationic salt forms
- prepare esters of S3QELs
- describe functionalization of hydroxyl and carboxyl groups
- prepare amides of S3QELs
- describe techniques for preparing amides
- combine S3QELs with pharmaceutically acceptable carrier
- list physiologically acceptable compounds
- describe role of carbohydrates in compositions
- describe role of antioxidants in compositions
- describe role of chelating agents in compositions
- describe role of low molecular weight proteins in compositions
- describe role of lipids in compositions
- describe role of protection and uptake enhancers in compositions
- describe role of excipients or other stabilizers and/or buffers in compositions
- list binders for oral dosage forms
- list disintegrants for oral dosage forms
- list lubricants for oral dosage forms
- list suspending agents for oral dosage forms
- describe manufacturing process for oral dosage forms
- describe systemic formulations for administration
- describe transdermal formulations for administration
- describe transmucosal formulations for administration
- describe oral formulations for administration
- describe rectal or vaginal formulations for administration
- describe depot preparations for administration
- describe liposomes and emulsions as delivery vehicles
- describe sustained-release systems for delivery
- describe protein stabilization strategies
- administer S3QELs orally
- describe enteric-coated particles
- administer S3QELs systemically
- describe transdermal drug delivery systems
- describe reservoirs in transdermal patches
- describe skin contact adhesive materials
- describe backing layers in transdermal patches
- provide S3QELs as a concentrate
- describe effective amount of S3QELs for pharmacological effect
- describe typical daily dose of S3QELs
- describe administration frequency of S3QELs
- formulate S3QELs in single oral dosage form
- describe solid and liquid oral formulations
- describe enteric-coated delayed-release granules
- describe non-enteric time-dependent release coatings

### Kits.

- provide agents in kits
- describe kit components
- specify container types
- include instructional materials
- warn of adverse reactions
- describe treatment methods
- specify packaging materials

## EXAMPLES

- provide illustrative examples

### Example 1

- introduce intestinal epithelial barrier
- describe importance of barrier function
- motivate oxidative stress as driver of barrier dysfunction
- introduce Drosophila and mice as models of metabolic disease and aging
- describe effect of dietary yeast extract on lifespan and intestinal permeability
- measure intestinal permeability using blue food dye
- analyze correlation between intestinal permeability and lifespan
- describe balance between cell proliferation and apoptosis in Drosophila intestine
- analyze effect of dietary yeast extract on apoptosis and proliferation
- confirm increase in intestinal permeability using gene expression hallmarks
- investigate mechanism of rich diet on median lifespan and intestinal permeability
- hypothesize role of mitochondrial superoxide production in intestinal permeability
- test effect of S3QELs on superoxide production and intestinal permeability
- analyze effect of S3QELs on apoptotic cell number and median lifespan
- investigate specificity of S3QELs to site IIIQo of complex III
- test effect of S3QELs on intestinal gene expression
- analyze effect of S3QELs on tight-junction gene expression
- investigate effect of S3QELs on antioxidant gene expression
- test effect of S3QELs on intestinal permeability in enterocytes
- analyze effect of S3QELs on superoxide levels in enterocytes
- investigate effect of S3QELs on median lifespan in enterocytes
- test effect of S3QELs in mouse model of high-fat diet
- analyze effect of S3QELs on intestinal permeability in mice
- investigate effect of S3QELs on tight-junction and mucin gene expression in mice
- analyze effect of S3QELs on glucose intolerance in mice
- investigate effect of S3QELs on body weight and adiposity in mice
- test effect of S3QELs on ER stress in mice
- summarize results of S3QELs on intestinal permeability and aging
- describe experimental design
- describe fly strains and husbandry
- describe experimental media and lifespan analysis
- describe fly lifespan assay
- describe intestinal permeability assay
- describe Acridine Orange/Ethidium Bromide staining
- describe Phosphohistone H3 staining
- describe fly food consumption assay
- describe mouse experiment setup
- describe FITC-Dextran assay
- describe fecal albumin assay
- describe glucose tolerance assay
- describe body fat measurement
- describe RNA and cDNA preparation
- describe quantitative real-time PCR
- describe statistical analysis
- discuss limitations of assays
- discuss application of results
- provide disclaimer and reference incorporation

